Article
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
The Lancet. Infectious diseases - 1 Apr 2015
Bourlière Marc, Bronowicki Jean-Pierre, de Ledinghen Victor, Hézode Christophe, Zoulim Fabien, Mathurin Philippe, Tran Albert, Larrey Dominique G, Ratziu Vlad, Alric Laurent, Hyland Robert H, Jiang Deyuan, Doehle Brian, Pang Phillip S, Symonds William T, Subramanian G Mani, McHutchison John G, Marcellin Patrick, Habersetzer François, Guyader Dominique, Grangé Jean-Didier, Loustaud-Ratti Véronique, Serfaty Lawrence, Metivier Sophie, Leroy Vincent, Abergel Armand, Pol Stanislas
Abstract excerpt
BACKGROUND: Patients with cirrhosis resulting from chronic hepatitis C virus (HCV) infection are at risk of life-threatening complications, but consistently achieve lower sustained virological response (SVR) than patients without cirrhosis, especially if treatment has previously failed. We assessed the efficacy and safety of the NS5A inhibitor ledipasvir and the nucleotide polymerase inhibitor sofosbuvir, with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.